In Brief: KeraVision
This article was originally published in The Gray Sheet
Executive Summary
KeraVision: Results of multi-center U.S. Phase III trial of firm's KeraVision ring show that 47% of 113 patients achieved "better than 20/20 vision" after three months of being treated for low nearsightedness (-1.0 to -3.5 diopters of myopic correction), while 97% achieved "at least 20/40 vision or better," according the company. KeraVision plans to seek FDA approval by the end of 1997 to expand its trial to include treating moderate nearsightedness (-3.5 to -5.0 diopters)...